Skip to main content
SpringerLink
Log in

Inhibition of platelet-derived mitogen release by nitric oxide (EDRF)

  • Mini-Papers Submitted for Scholarship Competition
  • Mediators
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Platelets exposed to thrombogenic surfaces adhere, aggregate and release mitogenic substances from their α-granules. Endothelium-derived relaxing factor (EDRF) which has been identified as nitric oxide (NO) has been reported to inhibit platelet aggregation. We now report that NO inhibits mitogen release from stimulated human platelets. Mitogenic activity was assayed on mouse fibroblast, 3T3 cells using incorporation of3H-thymidine. Serum from collagen-aggregated platelets significantly increased3H-thymidine incorporation by 3T3 cells above that of serum from control platelets. Both this increase and platelet aggregation were blocked by NO and prostacyclin in a dose related manner. The inhibitory activity of NO decayed with time when incubated in platelet-free plasma at 37°C, but was still detectable after 2 minutes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. R. Ross, E. W. Raines and D. F. Bowen-Pope,The biology of platelet-derived growth factor. Cell46, 155–169 (1986).

    Google Scholar 

  2. B. C. Berk, R. W. Alexander, T. A. Brock, M. A. Gimbrone Jr. and R. C. Webb,Vasoconstriction: a new activity for platelet-derived growth factor. Science232, 87–90 (1986).

    Google Scholar 

  3. R. M. J. Palmer, A. G. Ferrige and S. Moncada,Nitric oxide release accounts for the biological activity of endothelium-derived growth factor. Nature327, 524–526 (1987).

    Google Scholar 

  4. M. W. Radomski, R. M. J. Palmer and S. Moncada,Comparative pharmacologyof endothelium-derived relaxing factor, nitric oxide and prostacacyclin in platelets. Br. J. Pharmac.92, 181–187 (1987).

    Google Scholar 

  5. A. L. Willis, D. L. Smith and C. Vigo,Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids. Prog. Lipid Res.25, 645–666 (1986).

    Google Scholar 

  6. M. W. Radomksi, R. M. J. Palmer and S. Moncada,Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet, 1057–1058 (1987).

  7. U. Forstermann, A. Mugge, U. Alheid, a. Haverich and J. C. Frolich,Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circulation Res.62, 185–190 (1988).

    Google Scholar 

  8. J. Abrams,A reappraisal of nitrate therapy. JAMA259, 396–401 (1988).

    Google Scholar 

  9. S. Yusuf, R. Collins, S. MacMahon and R. Peto,Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet, 1088–1092 (1988).

Download references

Author information

Authors and Affiliations

  1. The William Harvey Research Institute, St. Bartholomew's Hospital Medical College, Charterhouse Square, EC1M 6BQ, London, UK

    M. L. Barrett & J. R. Vane

  2. Syntex Research Palo Alto, Institute of Biological Sciences, 94303, CA, USA

    A. L. Willis

Authors
  1. M. L. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. L. Willis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. R. Vane
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barrett, M.L., Willis, A.L. & Vane, J.R. Inhibition of platelet-derived mitogen release by nitric oxide (EDRF). Agents and Actions 27, 488–491 (1989). https://doi.org/10.1007/BF01972860

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01972860

Keywords

Search

Navigation